ABBV

AbbVie

$286.20

+0.94%
Nov 20, 2026
Bobby Quantitative Model
AbbVie is a global biopharmaceutical company focused on immunology (Skyrizi, Rinvoq, Humira), oncology (Imbruvica, Venclexta, Elahere), neuroscience (Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Vyalev), and medical aesthetics (Botox Cosmetic, Juvederm), operating in the large-cap drug manufacturing industry following its 2013 spin-off from Abbott and transformative 2020 Allergan acquisition. It is a scaled, dividend-paying pharma leader whose identity is increasingly defined by its post-Humira immunology franchise and a bolt-on M&A strategy (Cerevel, ImmunoGen, and the 2026 Apogee deal) that layers in neuroscience and oncology depth. The current investor narrative centers on whether Skyrizi and Rinvoq can more than offset the accelerating Humira erosion, with the most recent Q3 2026 print showing revenue and EPS beats alongside a sharp Humira decline that keeps sentiment split. Fresh catalysts include the FDA approval of the Parkinson's drug Juvmo (validating the Cerevel acquisition and framed as a potential $5 billion peak-sales asset) and the Apogee immunology acquisition, which together reinforce the growth-replacement story even as the stock trades near record highs.

People also watch

Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
Johnson & Johnson

Johnson & Johnson

JNJ

Analysis
Merck & Co.

Merck & Co.

MRK

Analysis
Amgen

Amgen

AMGN

Analysis
Gilead Sciences

Gilead Sciences

GILD

Analysis

BobbyInvestment Opinion: Should I buy ABBV Today?

Rating: Hold (with a constructive bias toward accumulating on weakness). The core thesis is that AbbVie's post-Humira growth replacement is now proven — Skyrizi ($5.776B) plus Rinvoq ($2.706B) generated $8.482B in Q3 2026, roughly 12.4x the shrunken $683M Humira franchise — but at $295.03 the stock already reflects much of that success, leaving only +5.7% upside to the $311.81 consensus target despite a 23-Buy/5-Hold/1-Sell consensus (recommendation mean 1.69). The business is executing; the price is full.

Supporting evidence is genuinely strong on fundamentals: Q3 2026 revenue of $17.404B grew 10.32% YoY with sequential expansion from $15.002B (Q1) to $16.990B (Q2), net margin recovered to 24.24% from 1.18% in the charge-laden Q3 2025, gross margin expanded to 75.38%, and trailing free cash flow is $18.872B against just $301M of quarterly capex. The forward PE of 18.22x on consensus EPS of $21.12 is undemanding for double-digit growth and is supported by a 2.88% dividend yield and 21.3x price-to-cash-flow floor. However, the 26.61x EV/EBITDA and 8.97x EV/Sales sit at a premium to the low-to-mid-teens EV/EBITDA typical of mature pharma peers, and the stock is up 27.01% over one year and 28.66% YTD, sitting only 2.6% below its $302.93 52-week high.

Three risks could invalidate the thesis: (1) immunology concentration — Skyrizi and Rinvoq are the entire growth engine, so any deceleration or pricing pressure hits directly; (2) balance-sheet strain from an acquisitive strategy — current ratio of 0.671, Q3 interest expense of $802M, and a $10.86B acquisition outflow (Apogee) mean FCF is partly committed to M&A; (3) valuation compression — the wide $237-$350 analyst target spread (roughly 48% of the current price) shows how quickly sentiment could de-rate. This Hold would upgrade to Buy on a pullback toward the $250-260 consolidation zone (implying ~20% upside to consensus) or on evidence that Skyrizi/Rinvoq growth is re-accelerating above 20%; it would downgrade to Sell if immunology growth decelerates below 10% or if margins compress on M&A dilution. Verdict: fairly valued to modestly rich relative to history and peers — a quality compounder priced for continued execution, not a bargain.

Sign up to view all

ABBV 12-Month Price Forecast

The fundamental trajectory favors the bulls — double-digit revenue growth, margins recovered to a 24.24% net and 36.01% operating level, $18.872B of trailing free cash flow, and a 2.88% dividend yield — but the risk/reward at $295.03 is far less compelling than earlier in the year. With the stock up 27.01% over twelve months, sitting near its 52-week high, and offering only single-digit upside to consensus, much of the good news appears priced in, and the 26.61x EV/EBITDA leaves little room for execution missteps. The decisive variable is whether Skyrizi/Rinvoq plus new launches (Juvmo, Apogee) can sustain double-digit growth fast enough to justify the premium as Humira fades; the wide $237-$350 target spread shows how quickly sentiment could compress if that momentum stalls. I would upgrade to bullish on a pullback toward the $250-260 consolidation zone or on evidence of re-accelerating immunology growth above 20%, and downgrade to bearish if immunology growth decelerates below 10% or margins compress on M&A dilution.

Historical Price
Current Price $286.20
Average Target $310.00
High Target $350.00
Low Target $237.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $315.88 and implied upside of +10.4% versus the current price.

Average Target

$315.88

29 analysts

Implied Upside

+10.4%

vs. current price

Analyst Count

29

covering this stock

Price Range

$237 - $350

Analyst target range

Buy
23 (79%)
Hold
5 (17%)
Sell
1 (3%)

Coverage is deep and overwhelmingly constructive: 26 analysts rate the stock, with 23 Buy, 5 Hold, and just 1 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.69 (where 1.0 is a strong buy). The average target price of $311.81 implies roughly +5.7% upside from the current $295.03, a modest but positive signal that suggests much of the near-term good news is already reflected after the 27% one-year run. The bullish tilt is reinforced by recent institutional actions — UBS and Goldman Sachs remain Neutral, but the bulk of the coverage universe (Morgan Stanley, Wells Fargo, RBC, Leerink, Cantor, Guggenheim, Barclays, Canaccord) reiterated Overweight/Buy/Outperform ratings around the November 2 Q3 print, indicating stable conviction rather than fresh upgrades. The target range is wide, from a low of $237.00 to a high of $350.00, a spread of roughly 48% of the current price that signals meaningful dispersion in assumptions. The $350 high target likely assumes sustained double-digit Skyrizi/Rinvoq growth, successful Juvmo and Apogee integration, multiple expansion toward premium pharma peers, and clean earnings normalization; the $237 low target implies Humira erosion outpaces new-product ramp, margin compression from M&A dilution, and a de-rating toward value-pharma multiples. The wide spread, combined with the modest implied upside to the average, argues for a balanced stance: the fundamental momentum and analyst consensus are supportive, but with the stock near its 52-week high and only single-digit upside to consensus, risk/reward is less compelling than it was earlier in the year.

Drowning in data?

Find the real signal!

Bulls vs Bears: ABBV Investment Factors

The bull case currently has the stronger evidence: revenue is growing 10.32% YoY, Skyrizi plus Rinvoq at $8.482B now dwarf Humira's $683M, margins have recovered to a 24.24% net and 36.01% operating level, and the forward PE of 18.22x is undemanding for that growth. The bear case rests less on fundamentals than on price and positioning — the stock is up 27.01% in a year, sits 2.6% below its 52-week high, offers only +5.7% upside to the $311.81 consensus target, and trades at a 26.61x EV/EBITDA premium. The single most important tension is whether Skyrizi/Rinvoq plus new launches (Juvmo, Apogee) can sustain double-digit growth fast enough to justify that premium as Humira fades — if immunology momentum holds, the multiple is defensible; if it decelerates, the wide $237-$350 target spread shows how quickly sentiment could compress. Net, the fundamental trajectory favors the bulls, but the risk/reward at $295 is far less compelling than it was earlier in the year.

Bullish

  • Immunology engine now dwarfs Humira: Skyrizi ($5.776B) and Rinvoq ($2.706B) together generated $8.482B in Q3 2026, roughly 12.4x the shrunken Humira franchise at $683M. The growth-replacement thesis is no longer theoretical — the new drugs already carry the franchise, and Humira's remaining drag is now small in absolute terms.
  • Revenue growth accelerating sequentially: Q3 2026 revenue of $17.404B rose 10.32% YoY and built on sequential expansion from $15.002B in Q1 to $16.990B in Q2. Consensus models $86.27B for the forward year, implying continued double-digit top-line momentum even as Humira approaches de minimis.
  • Margins recovering sharply off trough: Q3 2026 net income of $4.218B produced a 24.24% net margin versus just 1.18% in the charge-laden Q3 2025, while gross margin expanded from 71.88% in Q1 to 75.38% in Q3. Operating margin of 36.01% shows operating leverage returning as one-time IPR&D and impairment charges roll off.
  • Forward valuation is modest for the growth: The forward PE of 18.22x against consensus EPS of $21.12 is reasonable for a large-cap pharma growing revenue 10.3%, and the 96.4x trailing PE is distorted by prior-year charges rather than a true earnings picture. The 2.88% dividend yield and 21.3x price-to-cash-flow add a valuation floor.

Bearish

  • Only single-digit upside to consensus: The $311.81 average target implies just +5.7% from the $295.03 price after a 27.01% one-year and 28.66% YTD run. With the stock at roughly 93% of its 52-week range and only 2.6% below the $302.93 high, much of the near-term good news appears priced in.
  • EV/EBITDA premium leaves no slack: EV/EBITDA of 26.61x and EV/Sales of 8.97x sit well above the low-to-mid-teens EV/EBITDA typical of mature pharma peers. That premium prices in continued successful immunology conversion and leaves limited room for execution missteps.
  • Thin liquidity and heavy leverage: The current ratio of 0.671 and negative reported debt-to-equity (an artifact of negative book equity) flag a thin liquidity cushion for an acquisitive company. Q3 interest expense of $802M and a $10.86B acquisition outflow show FCF is partly committed to M&A rather than pure shareholder return.
  • Wide analyst dispersion signals uncertainty: Targets range from $237 to $350 — a spread of roughly 48% of the current price — reflecting genuine disagreement on whether Humira erosion outpaces new-product ramp. The $237 low target implies a de-rating toward value-pharma multiples and margin compression from M&A dilution.

ABBV Technical Analysis

AbbVie is in a sustained, powerful uptrend, with the stock up 27.01% over the past year and 28.66% year-to-date, and the current price of $295.03 sits at roughly 93% of its 52-week range (low $190.75 to high $302.93). That positioning near the top of the range signals strong momentum rather than a value entry point, though it also raises the risk of overextension given the stock is only about 2.6% below its 52-week high. The 6-month gain of 40.23% confirms the move is not a brief spike but a durable re-rating. Recent momentum is positive but decelerating: the 1-month change of 4.07% and 3-month change of 18.27% are both strong, yet the 1-month pace is markedly slower than the 3-month and 6-month rates, suggesting the steepest phase of the advance has passed. Critically, this strength is occurring against a weak tape — SPY is down 2.26% over 1 month and 2.83% over 3 months — producing relative strength of +6.33 (1M) and +21.10 (3M), evidence of genuine leadership and defensive rotation into pharma rather than beta-driven drift. Key resistance sits at the $302.93 52-week high; a clean breakout would confirm the uptrend and likely invite momentum buyers, while support rests near the $190.75 52-week low, with intermediate support implied around the $250 area where the stock consolidated in August. The reported beta of 0.192 is unusually low, implying the stock has historically moved with only about 19% of the market's volatility — a defensive characteristic that supports larger position sizing on a risk-adjusted basis but also means the recent 40% six-month run is idiosyncratic rather than market-driven. The max drawdown of -16.46% over the period underscores contained downside, consistent with a low-beta defensive compounder.

Beta

0.19

0.19x market volatility

Max Drawdown

-16.5%

Largest decline past year

52-Week Range

$191-$303

Price range past year

Annual Return

+24.7%

Cumulative gain past year

PeriodABBV ReturnS&P 500
1m+0.5%-9.7%
3m+8.0%-9.9%
6m+32.7%-7.5%
1y+24.7%+4.7%
ytd+24.8%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

ABBV Fundamental Analysis

Revenue is growing at a healthy clip, with Q3 2026 revenue of $17.404 billion up 10.32% year-over-year, and the multi-quarter trend shows steady sequential expansion from $15.002 billion in Q1 to $16.990 billion in Q2 to $17.404 billion in Q3 2026. The growth engine is clearly immunology — Skyrizi at $5.776 billion and Rinvoq at $2.706 billion — while the legacy Humira franchise has shrunk to just $683 million, confirming the portfolio transition is well advanced. Neuroscience is a meaningful second leg (Vraylar $1.068 billion, Botox Therapeutic $1.080 billion, Ubrelvy $449 million, Qulipta $398 million), and the Juvmo approval adds a fresh growth vector. The investment case hinges on whether Skyrizi/Rinvoq momentum plus new launches can sustain double-digit growth as Humira approaches a de minimis contribution. Profitability is robust and improving: Q3 2026 net income reached $4.218 billion (a 24.24% net margin), gross margin was 75.38%, and operating margin was 36.01%, all up sharply from the depressed Q3 2025 base when net income was just $186 million on a 1.18% net margin. The sequential recovery is striking — net income climbed from $699 million in Q1 to $3.613 billion in Q2 to $4.218 billion in Q3 — reflecting both operating leverage and the absence of the large IPR&D and impairment charges that crushed prior-year results. Gross margin has expanded from 71.88% in Q1 to 75.38% in Q3, and the trailing net margin of 6.91% understates current run-rate profitability given the charge-laden earlier quarters. Balance sheet and cash flow are solid but carry leverage typical of an acquisitive pharma: trailing free cash flow is $18.872 billion, Q3 operating cash flow was $7.606 billion against capex of just $301 million, and the company returned $3.071 billion in dividends in the quarter. The current ratio of 0.671 and negative reported debt-to-equity (an artifact of negative book equity from buybacks and impairments) flag a thin liquidity cushion and heavy debt load, but interest coverage remains comfortable and the dividend is well covered by cash flow. The Q3 acquisitions outflow of $10.86 billion (Apogee and related deals) shows management is willing to deploy balance-sheet capacity for growth, a strategic positive but a reminder that FCF is partly committed to M&A rather than pure shareholder return.

Quarterly Revenue

$17.4B

2026-09

Revenue YoY Growth

+10.3%

YoY Comparison

Gross Margin

75.4%

Latest Quarter

Free Cash Flow

$18.9B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Skyrizi
Rinvoq
Humira
Vraylar
Botox Therapeutic
Ubrelvy
Qulipta
Vyalev
Other Neuroscience
Venclexta
Imbruvica
Elahere
Epkinly
Other Oncology
Botox Cosmetic
Juvederm Collection
Other Aesthetics
Mavyret
Creon
Linzess
All other

Open an Account, get $2 TSLA now!

Valuation Analysis: Is ABBV Overvalued?

Because AbbVie is profitable on a trailing basis (net income positive), the PE ratio is the appropriate lead metric, but the trailing PE of 96.41x is distorted by the charge-laden prior-year quarters and should be discounted in favor of the forward PE of 18.22x. The enormous gap between trailing (96.4x) and forward (18.2x) multiples implies the market expects a dramatic earnings normalization — consistent with consensus EPS of $21.12 versus the trailing figure — reflecting the clean-up of one-time charges and the Skyrizi/Rinvoq growth ramp. On a forward basis, 18.2x is a reasonable, even modest, multiple for a large-cap pharma growing revenue double digits. Relative to the sector, the PS ratio of 6.63x and EV/Sales of 8.97x sit at a premium to typical large-cap drug manufacturers, and the EV/EBITDA of 26.61x is elevated versus the low-to-mid teens common for mature pharma peers. That premium is partly justified by AbbVie's above-sector revenue growth (10.3% YoY) and its 70.2% gross margin, but the 26.6x EV/EBITDA leaves limited room for execution missteps and prices in continued successful immunology conversion. Historically, AbbVie's own valuation band has been wide and volatile: quarterly PE ratios in the historical data range from roughly 15x (2022) to over 500x during charge-distorted quarters, and PS ratios have ranged from about 16x to 27x. The current PS of 6.63x appears low only because the provided valuation snapshot uses a different share-count basis than the historical series; on a like-for-like basis the stock is trading toward the upper end of its historical PS band, consistent with the market pricing in optimistic growth expectations near 52-week highs. The 2.88% dividend yield and 21.3x price-to-cash-flow offer a modest valuation floor for income investors.

PE

96.4x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 15x~139x

vs. Industry Avg

18.6x

Industry PE ~18.6x*

EV/EBITDA

26.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on leverage and the cost of an acquisitive strategy. The current ratio of 0.671 and negative reported debt-to-equity signal a thin liquidity cushion, while Q3 interest expense of $802M and a $10.86B acquisition outflow (Apogee and related deals) show free cash flow is partly committed to M&A rather than pure shareholder return. Earnings quality is also uneven — quarterly EPS swung from $0.39 in Q1 to $2.38 in Q3 2026, and the trailing net margin of 6.91% badly understates the current 24.24% run-rate, meaning headline multiples are distorted by charge timing. Finally, the franchise remains concentrated: immunology (Skyrizi $5.776B, Rinvoq $2.706B) is the growth engine, so any competitive or pricing pressure on those two drugs would hit the thesis directly. Market and competitive risks are dominated by valuation compression. At 26.61x EV/EBITDA and 8.97x EV/Sales, ABBV trades at a premium to mature pharma peers, and with only +5.7% upside to the $311.81 average target after a 27.01% one-year run, the stock is priced for continued execution. The beta of 0.192 means the recent 40.23% six-month gain is idiosyncratic rather than market-driven, so a rotation out of defensive pharma leadership — which has delivered +21.10 relative strength over three months against a weak SPY — could reverse gains quickly. Competitive threats include Humira biosimilar erosion (already down to $683M), pipeline setbacks in oncology (Imbruvica, Venclexta), and integration risk on Juvmo and Apogee, while the wide $237-$350 analyst target spread underscores how much assumptions diverge. The worst-case scenario is a chain in which Skyrizi/Rinvoq growth decelerates, Humira erosion proves stickier than modeled, and M&A dilution compresses margins, prompting a de-rating toward value-pharma multiples. In that path, the stock could retrace toward the $237 analyst low target, roughly -19.7% from $295.03, and in a deeper risk-off move toward the $190.75 52-week low, about -35.3%. The historical max drawdown of -16.46% over the period suggests such a move, while larger than recent experience, is well within the realm of a single disappointing earnings cycle.

FAQ

The most severe risk is immunology concentration: Skyrizi ($5.776B) and Rinvoq ($2.706B) are effectively the entire growth engine, so any competitive or pricing pressure on those two drugs hits the thesis directly and could drive the stock toward the $237 analyst low target. Second is balance-sheet and M&A risk — a current ratio of 0.671, Q3 interest expense of $802M, and a $10.86B acquisition outflow (Apogee) mean free cash flow is partly committed to deals, and integration dilution could compress the 24.24% net margin. Third is valuation compression: at 26.61x EV/EBITDA the stock trades at a premium to mature pharma peers, and with a beta of just 0.192 the 40.23% six-month gain is idiosyncratic, so a rotation out of defensive pharma leadership (which has delivered +21.10 relative strength over three months) could reverse gains quickly. Fourth is pipeline and execution risk in oncology (Imbruvica, Venclexta) and the Juvmo launch, where a setback would undercut the growth-replacement narrative. Ranked by severity: immunology concentration first, valuation compression second, M&A/leverage third, pipeline execution fourth.

The 12-month forecast splits into three scenarios. The base case (55% probability, $300-320) assumes Skyrizi/Rinvoq grow in the high-teens, forward EPS of $21.12 is met, and the stock grinds toward the $311.81 average target — about +5.7% from $295.03. The bull case (20% probability, $330-350) requires combined immunology growth above 20%, a credible Juvmo ramp toward $5B peak sales, and clean Apogee integration, driving multiple expansion toward the $350 high target (+18.6%). The bear case (25% probability, $237-260) assumes immunology decelerates, Humira erosion proves stickier, and M&A dilution compresses margins, retracing toward the $237 low target (-19.7%), with a deeper risk-off move toward the $190.75 52-week low (-35.3%) possible. The base case is most likely, and its key assumption is that earnings growth — not multiple expansion — does the work, keeping the forward PE near 18.2x.

The answer depends heavily on which multiple you anchor to, and the honest verdict is fairly valued to modestly rich. The forward PE of 18.22x on consensus EPS of $21.12 is undemanding for a business growing revenue 10.3%, and the 2.88% dividend yield plus 21.3x price-to-cash-flow provide a valuation floor. But the trailing PE of 96.41x is distorted by prior-year charges and should be discounted, while EV/EBITDA of 26.61x and EV/Sales of 8.97x sit well above the low-to-mid-teens EV/EBITDA typical of mature pharma peers. That premium implies the market expects the Skyrizi/Rinvoq ramp to fully offset Humira erosion and that new launches (Juvmo, Apogee) extend the growth runway — expectations that are plausible but leave little room for error. With the stock near its 52-week high and only +5.7% to the average target, the market is paying a fair-to-full price for continued execution rather than a discount.

From a risk/reward standpoint ABBV is a reasonable but not compelling buy at $295.03. The fundamental case is solid — revenue grew 10.32% YoY to $17.404B in Q3 2026, net margin recovered to 24.24%, and 23 of 26 analysts rate it Buy with a $311.81 average target — but that target implies only +5.7% upside after a 27.01% one-year and 28.66% YTD run, with the stock just 2.6% below its $302.93 52-week high. The biggest downside risk is a de-rating toward the $237 analyst low target, roughly -19.7%, if immunology growth stalls or M&A dilution compresses margins. It is a good buy for long-horizon, income-oriented investors comfortable with a low-beta (0.192) defensive compounder and a 2.88% yield, particularly on a pullback toward the $250-260 consolidation zone where upside to consensus widens to roughly 20%. It is a less attractive buy for investors chasing near-term upside, given the thin margin of safety at current levels.

ABBV is structurally a long-term holding rather than a short-term trading vehicle. Its beta of 0.192 means it moves with only about 19% of the market's volatility, its 2.88% dividend yield rewards patience, and its earnings visibility is supported by a proven immunology franchise ($8.482B in Q3 2026) plus a deep pipeline and bolt-on M&A strategy. The stock is in a mature growth phase — revenue up 10.32% YoY with margins recovering — rather than an early-stage hypergrowth profile, which suits multi-year compounding. Short-term traders face a poor setup: only +5.7% upside to the $311.81 consensus target, the stock 2.6% below its 52-week high, and a max drawdown of -16.46% over the period showing downside is contained but real. A suggested minimum holding period is 2-3 years, long enough for the Humira transition to fully play out and for Juvmo and Apogee to contribute, with accumulation on pullbacks toward the $250-260 zone improving the entry.